University General Hospital Attikon General Hospital Of West Attica H Agia Varvara

At University General Hospital Attikon General Hospital Of West Attica H Agia Varvara, studies in cardiovascular diseases focus on heart failure and the role of obesity in worsening outcomes. The research is designed to assess whether new treatments can better reduce hospital visits, cardiovascular complications, and death compared with current care.

• Heart failure with preserved or mildly reduced ejection fraction and obesity
• Improving outcomes in patients at high risk of cardiovascular events
• Testing a new therapy to reduce heart failure-related events

This work reflects a strong interest in finding more effective ways to manage complex heart conditions in adults treated through the 2nd Department of Internal Medicine.

Clinical trials in immune system diseases and inflammatory conditions include research on juvenile psoriatic arthritis and chronic spontaneous urticaria. These studies aim to improve symptom control, lower disease activity, and evaluate whether newer therapies can offer better relief than existing options.

• Juvenile psoriatic arthritis in children and adolescents
• Chronic spontaneous urticaria with long-term symptom burden
• Evaluating treatments that may improve immune-related disease control

The site is contributing to research that may help both pediatric and adult patients living with persistent inflammatory disease.

Research in nervous system diseases includes studies in secondary progressive multiple sclerosis, with the goal of slowing disability progression and delaying worsening of the disease. These trials are focused on testing whether emerging therapies can better preserve function and improve long-term outcomes.

• Secondary progressive multiple sclerosis
• Delaying disability progression
• Evaluating treatment effectiveness in progressive neurological disease

This area highlights the hospital’s role in advancing care for people with chronic neurological conditions that can become increasingly disabling over time.

A major part of the trial portfolio at this site involves neoplasms, including advanced non-small cell lung cancer, head and neck squamous cell carcinoma, early breast cancer, urothelial carcinoma, newly diagnosed AML, and Philadelphia-negative B-cell precursor acute lymphoblastic leukemia. The studies are mainly designed to test new therapies, compare them with current treatment options, and improve survival and disease control.

• Advanced non-small cell lung cancer and KRAS G12C mutation research
• Metastatic or recurrent head and neck cancer treatment studies
• Early breast cancer recurrence prevention
• Urothelial carcinoma and other blood cancer trials

These oncology trials show broad activity across solid tumors and hematologic cancers, with a clear focus on more effective and personalized treatment approaches.

Within respiratory tract diseases, the site is involved in trials for advanced non-small cell lung cancer, a serious cancer affecting the lungs. The research aims to improve first-line treatment options and evaluate whether newer combinations can provide better disease control and longer survival.

• Advanced non-small cell lung cancer
• Testing therapies for first-line treatment
• Comparing new approaches with standard care

This work supports ongoing efforts to refine treatment strategies for lung cancer patients in need of more effective options.

Trials in skin and connective tissue diseases include research on chronic spontaneous urticaria and juvenile psoriatic arthritis. The main purpose is to evaluate how well new therapies can reduce symptoms, improve quality of life, and support longer-lasting disease control.

• Chronic spontaneous urticaria
• Juvenile psoriatic arthritis
• Assessing treatment benefit in inflammatory skin and joint disease

These studies add to the site’s broad portfolio of immune-related research and its focus on conditions that affect daily functioning and comfort.